daunorubicin has been researched along with vorinostat in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Canzoneri, JC; Guerrant, W; Oyelere, AK; Patil, V | 1 |
| Chakrabarti, A; Duclaud, S; Erdmann, F; Hauser, AT; Heimburg, T; Jung, M; Lancelot, J; Marek, M; Melesina, J; Pierce, RJ; Robaa, D; Romier, C; Schmidt, M; Shaik, TB; Sippl, W | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chatterjee, DR; Contractor, D; Jain, A; Kumar, D; Nagpure, M; Rana, P; Satpute, DP; Vaidya, GN; Venkatesh, A | 1 |
| Guo, W; Huang, J; Huang, S; Huang, X; Jin, J; Li, F; Li, X; Ling, Q; Pan, J; Ye, W | 1 |
2 review(s) available for daunorubicin and vorinostat
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Paradigm shift of "classical" HDAC inhibitors to "hybrid" HDAC inhibitors in therapeutic interventions.
Topics: Animals; Cardiovascular Diseases; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Molecular Targeted Therapy; Neoplasms; Nervous System Diseases | 2021 |
4 other study(ies) available for daunorubicin and vorinostat
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
Topics: Acetylation; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell-Free System; Cyclin-Dependent Kinase Inhibitor p21; Daunorubicin; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Models, Molecular; Structure-Activity Relationship; Topoisomerase Inhibitors; Tubulin; Vorinostat | 2012 |
Structure-Based Design and Synthesis of Novel Inhibitors Targeting HDAC8 from Schistosoma mansoni for the Treatment of Schistosomiasis.
Topics: Animals; Dose-Response Relationship, Drug; Drug Delivery Systems; Helminth Proteins; Histone Deacetylases; Humans; Larva; Models, Molecular; Schistosoma mansoni; Schistosomiasis mansoni; Schistosomicides; Structure-Activity Relationship; Substrate Specificity; X-Ray Diffraction | 2016 |
Novel SAHA‑bendamustine hybrid NL‑101 in combination with daunorubicin synergistically suppresses acute myeloid leukemia.
Topics: Animals; Bendamustine Hydrochloride; Cell Line, Tumor; Cell Proliferation; Cell Survival; Daunorubicin; DNA Damage; Drug Synergism; Female; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mice; Vorinostat; Xenograft Model Antitumor Assays | 2020 |